Papers by Vaishnavi Thakur
More than a decade ago, a discovery surprised the scientific world that even mature, adult somati... more More than a decade ago, a discovery surprised the scientific world that even mature, adult somatic cells
can be reprogrammed to be able to behave like pluripotent embryonic cells and can be differentiated
along alternative cell lineages. This indeed opened new avenues of personalized cell-based therapies
treating a wide range of diseases. This enthusiasm even grew stronger with rapid advances in
technology like DNA editing and the creation of diseased models. The effective differentiation capacity
of human induced pluripotent stem cells, commonly known as iPSCs has turned out to be the hallmark
of organoid model generation and their clinical utility.
The progress so far
Ever since researchers successfully isolated human embryonic stem cells in 1998, much focus was on
using them for therapeutic applications. Various studies have demonstrated techniques to successfully
isolated these stem cells and how they can further be differentiated into almost all types of cells,
including neural stem cells, cardiac progenitor cells, pancreatic stem cells, etc. This was definitely
leveraged into the creation of early embryonic stem cell-based diseased models (Clevers H.; 2015).
Bookmarks Related papers MentionsView impact
Uploads
Papers by Vaishnavi Thakur
can be reprogrammed to be able to behave like pluripotent embryonic cells and can be differentiated
along alternative cell lineages. This indeed opened new avenues of personalized cell-based therapies
treating a wide range of diseases. This enthusiasm even grew stronger with rapid advances in
technology like DNA editing and the creation of diseased models. The effective differentiation capacity
of human induced pluripotent stem cells, commonly known as iPSCs has turned out to be the hallmark
of organoid model generation and their clinical utility.
The progress so far
Ever since researchers successfully isolated human embryonic stem cells in 1998, much focus was on
using them for therapeutic applications. Various studies have demonstrated techniques to successfully
isolated these stem cells and how they can further be differentiated into almost all types of cells,
including neural stem cells, cardiac progenitor cells, pancreatic stem cells, etc. This was definitely
leveraged into the creation of early embryonic stem cell-based diseased models (Clevers H.; 2015).
can be reprogrammed to be able to behave like pluripotent embryonic cells and can be differentiated
along alternative cell lineages. This indeed opened new avenues of personalized cell-based therapies
treating a wide range of diseases. This enthusiasm even grew stronger with rapid advances in
technology like DNA editing and the creation of diseased models. The effective differentiation capacity
of human induced pluripotent stem cells, commonly known as iPSCs has turned out to be the hallmark
of organoid model generation and their clinical utility.
The progress so far
Ever since researchers successfully isolated human embryonic stem cells in 1998, much focus was on
using them for therapeutic applications. Various studies have demonstrated techniques to successfully
isolated these stem cells and how they can further be differentiated into almost all types of cells,
including neural stem cells, cardiac progenitor cells, pancreatic stem cells, etc. This was definitely
leveraged into the creation of early embryonic stem cell-based diseased models (Clevers H.; 2015).